Literature DB >> 9849583

Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18.

M Kohyama1, K Saijyo, M Hayasida, T Yasugi, M Kurimoto, T Ohno.   

Abstract

Direct activation of human cytotoxic T lymphocytes (CTL) by interleukin (IL)-18 was observed in a system in which CTL effective against autologous tumor cells were generated. Peripheral blood mononuclear cells (PBMC) from tumor-bearing patients, after removal of natural killer (NK) cells, were cultured in a medium containing IL-1, -2, -4, and -6, with or without IL-18, and stimulated with autologous tumor cells. IL-18 increased the activity of the CTL and the proportion of autologous CD8+ T cells present after 28 days in the induction culture. When purified CD8+ T cells were cultured in the presence of IL-18 and IL-2 for 7 days, the CTL showed enhanced cytotoxic activity against autologous tumor cells. Moreover, a purified CD8+ T cell population, which did not exhibit any apparent cytotoxic activity against autologous tumor cells, displayed cytotoxic activity after 7-day incubation with IL-18. These results suggest that IL-18 may be useful to generate autologous CTL in humans and may thereby contribute to adoptive immunotherapy for tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849583      PMCID: PMC5921705          DOI: 10.1111/j.1349-7006.1998.tb00494.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  25 in total

1.  Effects of interferon-gamma on the activation of human T lymphocytes.

Authors:  J P Siegel
Journal:  Cell Immunol       Date:  1988-02       Impact factor: 4.868

2.  Tumor-specific autologous cytotoxic T lymphocytes from tissue sections.

Authors:  S Q Liu; H Shiraiwa; K Kawai; H Hayashi; H Akaza; B S Kim; A Oki; M Nishida; T Kubo; K Hashizaki; K Saijo; T Ohno
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

3.  Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.

Authors:  M J Micallef; T Tanimoto; K Kohno; M Ikeda; M Kurimoto
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

4.  IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.

Authors:  H Tsutsui; K Nakanishi; K Matsui; K Higashino; H Okamura; Y Miyazawa; K Kaneda
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

5.  Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors.

Authors:  S Chouaib; J Chehimi; L Bani; N Genetet; T Tursz; F Gay; G Trinchieri; F Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Authors:  S L Topalian; L M Muul; D Solomon; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-08-24       Impact factor: 2.303

7.  Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas.

Authors:  T Yamasaki; H Handa; J Yamashita; Y Watanabe; Y Namba; M Hanaoka
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

8.  Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme.

Authors:  H Tsurushima; S Q Liu; K Tsuboi; Y Yoshii; T Nose; T Ohno
Journal:  J Neurosurg       Date:  1996-02       Impact factor: 5.115

9.  In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.

Authors:  M Nakashima; T Watanabe; H Koprowski; L Schuchter; Z Steplewski
Journal:  Cell Immunol       Date:  1994-04-15       Impact factor: 4.868

10.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  7 in total

1.  Recycled addition of CD4+ T cell-rich population for induction of human autologous cytotoxic T lymphocytes: A practically efficient method.

Authors:  K Saijo; H Tsurushima; K Tsuboi; T Nose; A Oki; T Ohno
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

2.  Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.

Authors:  Ryuya Yamanaka; Junpei Honma; Naoto Tsuchiya; Naoki Yajima; Tsutomu Kobayashi; Ryuichi Tanaka
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

3.  The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma.

Authors:  Zhao-Hui Tang; Wen-Hong Qiu; Gao-Song Wu; Xiang-Ping Yang; Sheng-Quan Zou; Fa-Zu Qiu
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

4.  Interleukin-18 is regulated by G protein pathways and protein kinase signals in human fibroblasts.

Authors:  Marc K Schuler; Wilhelm K Aicher
Journal:  Rheumatol Int       Date:  2003-07-15       Impact factor: 2.631

5.  A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients.

Authors:  Yong Seok Kim; Jae Youn Cheong; Sung Won Cho; Kee Myung Lee; Jae Chul Hwang; Bermseok Oh; Kuchan Kimm; Jung A Lee; Byung Lae Park; Hyun Sub Cheong; Hyoung Doo Shin; Jin Hong Kim
Journal:  Dig Dis Sci       Date:  2009-09-12       Impact factor: 3.199

6.  Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin.

Authors:  W P Wang; M Iigo; J Sato; K Sekine; I Adachi; H Tsuda
Journal:  Jpn J Cancer Res       Date:  2000-10

7.  A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model.

Authors:  Kosuke Higashi; Shoichi Hazama; Atsuhiro Araki; Kiyoshi Yoshimura; Norio Iizuka; Shigefumi Yoshino; Takafumi Noma; Masaaki Oka
Journal:  Int J Oncol       Date:  2014-07-22       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.